Co-occurrence of extended spectrum β lactamase and MCR-1 encoding genes on plasmids

Haenni, Marisa; Poirel, Laurent; Kieffer, Nicolas; Châtre, Pierre; Saras, Estelle; Métayer, Véronique; Dumoulin, Romain; Nordmann, Patrice; Madec, Jean‐Yves

doi:10.1016/s1473-3099(16)00007-4

Cited by 184 publications

(156 citation statements)

References 1 publication

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…This suggests that the use of extended-spectrum cephalosporins may have simultaneously favored the spread of mcr-1. This hypothesis is also supported by previous data demonstrating the colocalization in E. coli of mcr-1 and bla ESBL genes on a unique IncHI2/ST4 plasmid in French calves (3,7).…”

supporting

confidence: 87%

Increasing Trends in mcr-1 Prevalence among Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from French Calves despite Decreasing Exposure to Colistin

Haenni

Métayer

Madec

2016

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

b Since the first description of the plasmid-mediated colistin resistance gene (mcr-1), over 30 follow-up reports have proved the worldwide geographical distribution of this gene (1, 2). The overall picture indicates a very low prevalence in animals, human beings, and retail food, with two exceptions, the first in China, where mcr-1 carriage was observed in 21% and 15% of the animals and raw meat samples, and the second in France, where 21% of the extended-spectrum-␤-lactamase (ESBL)-producing Escherichia coli isolates from calves were mcr-1 positive (1, 3).

show abstract

supporting

confidence: 87%

Increasing Trends in mcr-1 Prevalence among Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from French Calves despite Decreasing Exposure to Colistin

Haenni

Métayer

Madec

2016

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, the mcr-1 gene has already been detected in multidrugresistant E. coli isolates that also contain an extended-spectrum β-lactamase or a carbapenemase enzyme. [12][13][14][15] Plasmid-mediated colistin resistance attributed to a second mcr gene (mcr-2) has also recently been described. 16 Many clinical microbiology laboratories do not test colistin routinely against E. coli, so the frequency with which resistance occurs in Canada is difficult to estimate from local data.…”

Section: -11mentioning

confidence: 99%

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015)

et al. 2016

View full text Add to dashboard Cite

Background: Colistin is often used as an antimicrobial of last resort for the treatment of infections caused by multidrug-resistant gram-negative bacilli. In 2015, plasmid-mediated colistin resistance in Escherichia coli due to MCR-1 was described. The purpose of this study was to evaluate the frequency of colistin resistance among E. coli clinical isolates obtained from patients in Canadian hospitals as part of the Canadian Ward Surveillance Study (CANWARD) and to determine how often the mcr-1 gene is detected among the colistin-resistant subset. Methods:From January 2008 to December 2015 (excluding 2011), 10 to 15 sentinel hospitals submitted consecutive clinical isolates (1 per patient per infection site) from blood (100-240), respiratory (100-150), urine (25-100) and wound (25-100) infections. We performed susceptibility testing using Clinical and Laboratory Standards Institute broth microdilution methods. Isolates that showed resistance to colistin as defined by European Committee on Antimicrobial Susceptibility Testing breakpoints (minimum inhibitory concentration ≥ 4 µg/mL) were evaluated for the mcr-1 gene by polymerase chain reaction. Results:In total, 5571 E. coli clinical isolates were obtained over the study years. Twelve isolates (0.2%) were resistant to colistin. The proportion of colistin-resistant isolates varied from 0.0% to 0.5% depending on the study year, and there was no clear trend toward increasing resistance over time. Typically the colistin-resistant isolates remained susceptible to antimicrobials from several other classes. Two colistin-resistant isolates (0.04%) were found to harbour the mcr-1 gene. Interpretation:The results suggest that colistin resistance among E. coli human clinical isolates, including resistance mediated by the mcr-1 gene, remains rare in Canada. AbstractResearch Research CMAJ OPEN E642CMAJ OPEN, 4(4)to MCR-1. MCR-1 (encoded for by the mcr-1 gene) is a member of the phosphoethanolamine transferase enzyme family. It confers resistance to colistin by the transfer of phosphoethanolamine to lipid A, thereby reducing the affinity of the target (by reducing the negative charge) for this polycationic antimicrobial. 7 E. coli isolates with the mcr-1 gene typically have colistin minimum inhibitory concentrations (MICs) in the range of 4 to 8 µg/mL. 7-11The location of the mcr-1 gene on a plasmid is concerning, as this raises the possibility that the resistance determinant may be transferred to multidrug-resistant gram-negative bacteria. Indeed, the mcr-1 gene has already been detected in multidrugresistant E. coli isolates that also contain an extended-spectrum β-lactamase or a carbapenemase enzyme.12-15 Plasmid-mediated colistin resistance attributed to a second mcr gene (mcr-2) has also recently been described. 16 Many clinical microbiology laboratories do not test colistin routinely against E. coli, so the frequency with which resistance occurs in Canada is difficult to estimate from local data. The purpose of this study was to evaluate the frequency of colistin res...

show abstract

“…Polymyxins (e.g., colistin and polymyxin B) are now more frequently used as last-resort antibiotics for treating patients with multidrug-resistant bacterial infections [7]. However, a recent report shows that a novel gene (mcr-1) as a source of plasmid-encoded resistance encoded on a plasmid in E. coli may quickly spread to other bacterial strains or species [8][9][10]. Therefore, due to the increasing threat of multidrug-resistant and pandrug-resistant bacteria, there is a need for novel molecules.…”

Section: Introductionmentioning

confidence: 99%

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

Dobiáš

Denervaud-Tendon

Poirel

et al. 2017

Eur J Clin Microbiol Infect Dis

129

View full text Add to dashboard Cite

The novel siderophore cephalosporin cefiderocol (S-649266) with potent activity against Gram-negative pathogens was recently developed (Shionogi & Co., Ltd.). Here, we evaluated the activity of this new molecule and comparators against a collection of previously characterized Gram-negative isolates using broth microdilution panels. A total of 753 clinical multidrug-resistant Gram-negative isolates collected from hospitals worldwide were tested against cefiderocol and antibiotic

show abstract

Co-occurrence of extended spectrum β lactamase and MCR-1 encoding genes on plasmids

Cited by 184 publications

References 1 publication

Increasing Trends in mcr-1 Prevalence among Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from French Calves despite Decreasing Exposure to Colistin

Increasing Trends in mcr-1 Prevalence among Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from French Calves despite Decreasing Exposure to Colistin

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015)

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

Contact Info

Product

Resources

About